The short version of NAD+ fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-09 and is reviewed periodically as new material appears.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C11H15N2O8P | Pyridinium nucleotide; free acid form |
| Molar mass | 334.22 g/mol | Free acid; salt forms differ |
| Appearance | White to off-white powder | Typical reference material |
| Solubility class | Water-soluble | Hygroscopic under humid conditions |
| Common synonyms | Nicotinamide mononucleotide; NMN | Distinct from nicotinamide riboside |
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
=== BPI lawsuit === On September 13, 2012, BPI announced that it filed a $1.2 billion lawsuit, Beef Products, Inc. v. American Broadcasting Companies, Inc., against ABC News; three reporters (Diane Sawyer, Jim Avila and David Kerley) and others, claiming ABC News made nearly "200 false, misleading and defamatory statements, repeated continuously during a month-long disinformation campaign", engaged in "product and food disparagement, and tortious interference with business relationships". BPI called the ABC News series a "concerted disinformation campaign" against LFTB. ABC News denied BPI's claims, and called the lawsuit without merit. ABC News sought to have the case removed from South Dakota state court to federal court. In June 2013, a federal judge sent the lawsuit back to state court. On March 27, 2014, South Dakota state court Judge Cheryle Gering rejected ABC's motion to dismiss, and allowed the defamation suit to move forward. Diane Sawyer's motion for summary judgment was granted and she was dismissed. The trial of the case began June 5, 2017, in Elk Point, South Dakota. The trial, in a courthouse remodeled for the occasion, was expected to take 8 weeks, but was settled after three weeks. The court ruled that BPI is a public figure; thus, proof of "actual malice" is required to support a verdict of defamation. ABC was represented by Williams & Connolly, BPI by Winston & Strawn. South Dakota has a food disparagement law which may have permitted triple damages to $5.7 billion had there been a verdict for the plaintiff.
The most common adverse effects of short-term use include headache (reported by 7% of people in clinical trials), drowsiness (2%), dizziness (1%), and diarrhea (1%); the most common side effects of long-term use included drowsiness (8%), dizziness (5%), allergy (4%), sinusitis (4%), back pain (3%), diarrhea (3%), drugged feeling (3%), dry mouth (3%), lethargy (3%), sore throat (3%), abdominal pain (2%), constipation (2%), heart palpitations (2%), lightheadedness (2%), rash (2%), abnormal dreams (1%), amnesia (1%), chest pain (1%), depression (1%), flu-like symptoms (1%), and sleep disorder (1%). Zolpidem increases the risk of depression, falls and bone fracture, poor driving, suppressed respiration and has been associated with an increased risk of death. Upper and lower respiratory infections are also common (experienced by 1–10% of people). Residual 'hangover' effects, such as sleepiness and impaired psychomotor and cognitive function, may persist into the day following nighttime administration. Such effects may impair the ability of users to drive safely and increase risks of falls and hip fractures. In January 2013, the FDA issued a safety communication addressing next-morning cognitive impairment associated with the drug. In May 2013, the FDA recommended avoiding activities requiring alertness the day after using extended-release formulations.
8 July An infantry battalion numbering 814 men from the US Army's 9th Infantry Division, the first of 25,000 American troops to be withdrawn from South Vietnam, arrived at McChord Air Force Base at 18:30 in a C-141 transport plane.
Sources: en.wikipedia.org
With its weight rested on the pelvis, it may have been free to move the hindlimbs. Getting back up again might have involved some stabilization from the diminutive forelimbs. The latter known as Newman's pushup theory has been debated. Nonetheless, Tyrannosaurus was probably able to get up if it fell, which only would have required placing the limbs below the center of gravity, with the tail as an effective counterbalance. Healed stress fractures in the forelimbs have been put forward both as evidence that the arms cannot have been very useful and as evidence that they were indeed used and acquired wounds, like the rest of the body.
== Epidemiology == In the United States, the incidence of osteogenesis imperfecta is estimated to be one per 20,000 live births. An estimated 20,000 to 50,000 people are affected by OI in the United States. The most common types are I, II, III, and IV, while the rest are very rare. Type I is the most common and has been reported to be around three times more common than type II. The prevalence of types III and IV is less certain. In a 1989 study in Denmark, type I was found to comprise 71% of cases and type II 12% of cases, with other types comprising the other 17%. In a 2015 study in Sweden, type I was nearly six times more common than type III and nearly four times more common than type IV. Most people with OI receive it from a parent, but in many cases, it is a brand new (de novo or "sporadic") mutation in a family. Among a study of patients with survivable types of OI, OI type III is most often de novo (85%), followed by type IV (50%) and type I (34%). Some populations can have a higher incidence of OI than would be otherwise expected if they have a larger-than-average number of carriers of the recessive forms of the disease.
Technetium (43Tc) is one of the two elements with Z < 83 that have no stable isotopes; the other such element is promethium. It is primarily artificial, with only trace quantities existing in nature produced by spontaneous fission (there are an estimated 2.5×10−13 grams of 99Tc per gram of pitchblende) or neutron capture by molybdenum. The element was first obtained in 1936 from bombarded molybdenum, the first artificial element to be produced. The most stable radioisotopes are 97Tc (half-life of 4.21 million years), 98Tc (half-life: 4.2 million years), and 99Tc (half-life: 211,100 years). Given that their stated uncertainties are 16 and 30 times their difference, the half-lives of 97Tc and 98Tc are statistically indistinguishable. Thirty-three other radioisotopes have been characterized with atomic masses ranging from 85Tc to 120Tc. Those with half-lives more than an hour have masses 93 to 96. Technetium also has numerous meta states. 97mTc is the most stable, with a half-life of 91.1 days (0.097 MeV), followed by 95mTc (half-life: 62.0 days, 0.039 MeV) and 99mTc (half-life: 6.01 hours, 0.143 MeV). 99mTc emits only gamma rays while decaying to 99Tc. For isotopes lighter than 98Tc, the primary decay mode is electron capture to isotopes of molybdenum. For the heavier isotopes, the primary mode is beta emission to isotopes of ruthenium, with the exception that 98Tc and 100Tc can decay both by beta emission and electron capture. Technetium-99m is the technetium isotope employed in the nuclear medicine industry.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in the cellular production of NAD+.
No. NMN is a smaller precursor molecule, while NAD+ is a dinucleotide cofactor used in many reactions. Enzymes called NMNAT convert NMN into NAD+ inside cells.
This question is not fully settled. Some evidence suggests NMN may be dephosphorylated to nicotinamide riboside before uptake, while other studies propose direct transport. Tissue-specific handling in humans remains an open research area.
NMN is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis. It consists of nicotinamide attached to a ribose phosphate unit. Cells produce it through the salvage pathway.